Comparative Evaluation of Large Language Models in Assessing Off-label Drug Use and Generating Patient Consent Forms: A Cross-sectional Study.
Main Article Content
Keywords
OLDU, Off-label drug use, Decision-making, Artificial intelligence, AI
Abstract
Background: Off-label drug use (OLDU) involves the prescription of medications beyond their approved indications, populations, or dosages, and is a common practice in areas such as pediatrics, geriatrics, psychiatry, and oncology. Ethical OLDU necessitates sound clinical justification and transparent, patient-centered consent. With the rise of large language models (LLMs) in healthcare, their utility in supporting OLDU through evidence synthesis and consent documentation remains underexplored. Methods: A cross-sectional study was conducted evaluating the performance of two LLMs, ChatGPT-4.0 and DeepSeek-V3, across seven OLDU scenarios encompassing vulnerable populations and emerging indications. Each LLM was prompted to assess OLDU using the BRAvO decision-making framework based on the PrOACT-URL structure and to generate corresponding patient consent forms. Fifteen standardized prompts were used, and responses were evaluated using rubric-based scoring systems for clinical reasoning (maximum score = 27) and consent form quality (maximum score = 33 when reproductive concern was applicable and 30 for others). Results: Both LLMs provided structured and complete responses across all scenarios. ChatGPT demonstrated superior readability, empathetic tone, and patient-focused consent forms, consistently scoring in the excellent range. DeepSeek provided higher clinical detail and included extensive guideline references, with strong medico-legal structuring in its documentation. Scenario-specific variations were noted in how each LLM addressed uncertainties, risk mitigation, and reproductive considerations. Overall, both models scored within the excellent range for OLDU assessment and consent generation. Conclusion: LLMs such as ChatGPT and DeepSeek can effectively support OLDU decision-making and informed consent processes. Their integration into clinical workflows offers promise, though expert oversight remains essential to ensure accuracy, ethical compliance, and patient-centered care.
References
2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021– 1026.
3. Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018 Feb;94:35-45.
4. Yackey K, Stukus K, Cohen D, Kline D, Zhao S, Stanley R. Off-label Medication Prescribing Patterns in Pediatrics: An Update. Hosp Pediatr. 2019 Mar;9(3):186-193.
5. Hoon D, Taylor MT, Kapadia P, Gerhard T, Strom BL, Horton DB. Trends in off-label drug use in ambulatory settings: 2006–2015. Pediatrics 2019; 144:e20190896.
6. Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017 Jun;42(3):251-258.
7. Sadjadi R, Cogdell E, Mostafa ME, Anatelli F, Ackerman L, Wijarnpreecha K, Han MAT. Drug Reaction With Eosinophilia and Systemic Symptoms and Severe Drug-Induced Liver Injury After Off-Label Zonisamide Use for Weight Loss. ACG Case Rep J. 2025 May 24;12(6):e01715.
8. Cook RJ. Off-label drug use as a consent and health regulation issue in New Zealand. J Bioeth Inq. 2015 Jun;12(2):251-8.
9. Zheng Z, Yang M, Wu J. Ethical Off-label Drug use: Need for a Rethink? Indian Pediatr. 2017 Jun 15;54(6):447-450.
10. Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, Zhao W, De Cock P, de Wildt SN, Allegaert K, van den Anker J. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020 May;179(5):839-847.
11. Basak R, Bentley JP, McCaffrey DJ 3rd, Bouldin AS, Banahan BF 3rd. The role of perceived impact on relationship quality in pharmacists’ willingness to influence indication-based off-label prescribing decisions. Soc Sci Med. 2015 May;132:181-9.
12. Zhang K, Meng X, Yan X, Ji J, Liu J, Xu H, Zhang H, Liu D, Wang J, Wang X, Gao J, Wang YG, Shao C, Wang W, Li J, Zheng MQ, Yang Y, Tang YD. Revolutionizing Health Care: The Transformative Impact of Large Language Models in Medicine. J Med Internet Res. 2025 Jan 7;27:e59069.
13. Sridharan K, Sivaramakrishnan G. Unlocking the potential of advanced large language models in medication review and reconciliation: A proof-of-concept investigation. Explor Res Clin Soc Pharm. 2024 Aug 17;15:100492.
14. Sridharan K, Sivaramakrishnan G. Investigating the capabilities of advanced large language models in generating patient instructions and patient educational material. Eur J Hosp Pharm. 2024 Dec 30:ejhpharm-2024-004245. 15. van der Zanden TM, Mooij MG, Vet NJ, Neubert A, Rascher W, Lagler FB, Male C, Grytli H, Halvorsen T, de Hoog M, de Wildt SN. Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework. Clin Pharmacol Ther. 2021 Oct;110(4):952- 965.
16. PROTECT. Pharmacoepidemiological research on outcomes of therapeutics by a European consortium.
17. Checklist for written consent: Unregistered use of medicine.
18. Off-label drugs. Educational material and consent form.
19. Off label use of drug or device. (accessed on May 27, 2025).
20. Lehman K, Aroney E. A guided framework for assessing off-label medication use in psychiatry. Australasian Psychiatry. 2024 Feb;32(1):63-7.
21. Gazarian M, Horton DB, Carleton B, Kinlaw AC, Bushnell GA, Czaja AS, Durrieu G, Gorman EF, Titievsky L, Zito J, Slaughter JL, dosReis S. Optimizing therapeutic decision-making for off-label medicines use: A scoping review and consensus recommendations for improving practice and research. Pharmacoepidemiol Drug Saf. 2023 Nov;32(11):1200-1222.
22. Morden NE, Schwartz LM, Fisher ES, et al. Accountable prescribing. N Engl J Med 2013; 369(4): 299–302.
23. Day RO. Ongoing challenges of off-label prescribing. Aust Prescr 2023;46:86-9.
24. Sofat R, Cremers S, Ferner RE. Drug and therapeutics committees as guardians of safe and rational medicines use. Br J Clin Pharmacol. 2020 Jan;86(1):10-12.
25. Sridharan K, Sivaramakrishnan G. Leveraging artificial intelligence to detect ethical concerns in medical research: a case study. Journal of Medical Ethics. 2025 Feb 1;51(2):126-34.
26. Vargas-Rivas JE, Sabater-Hernández D, Calleja-Hernández MA, Faus MJ, Martínez-Martínez F. Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use. International Journal of Clinical Pharmacy. 2011 Oct;33:719-21.
